RCEL - NASDAQ
AVITA Medical, Inc.
$4.16
-5.0%AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
At a Glance
Live SnapshotAVITA Medical, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
AVITA Medical, Inc. Cash Flow Statement
RCEL • NASDAQ
| AVITA Medical, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-48.6M | -61.8M | -35.4M | -26.7M | -25.1M | -26.6M | -42M | -25.1M | -9.4M | -8.8M | -5.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2M | 1.1M | 632K | 568K | 969K | 715K | 465K | 269K | 81K | 107.4K | 62.5K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -129K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
9.5M | 13.5M | 8.4M | 7M | 6.3M | 5.7M | 16.6M | 1.9M | 0.0 | 1.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.4M | 3M | -5.1M | 1.2M | 1.5M | 1.7M | 895K | 494K | 365.1K | 0.0 | 377.8K | -4.9M | -6.5M | -6.7M | -4.3M | -3.1M | -1.4M | -3.7M | -3.5M | -7.6M | |
(0.0) | (41K) | (44K) | (17K) | (0.0) | (42K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.5M | -129.3K | -90.1K | -85.5K | -92K | -296.8K | -126.9K | -604.1K | -420.3K | |
3.4M | -4.7M | -6.6M | -1.2M | -1.7M | -7.4M | 1.3M | 3.3M | -611.7K | 942.5K | -560.2K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-31.2M | -48.9M | -38M | -19.1M | -18M | -25.9M | -22.7M | -19.3M | -9.5M | -6.6M | -5.9M | -4.9M | -6.5M | -6.7M | -4.3M | -3.1M | -1.4M | -3.7M | -3.5M | -7.6M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | -9.2M | -1.4M | -452K | -487K | -894K | -590K | (0.0) | -268.7K | (0.0) | (0.0) | -22.5K | -66.8K | -70.5K | -78.3K | -95.4K | -59.9K | -57K | -103.3K | -67.8K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (41.8K) | (0.0) | |
-13.3M | -24.5M | -78.8M | -74.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
27.5M | 71.2M | 81.8M | 55.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.7M | -162K | -66K | -73K | -49.7M | -280K | -257K | 0.0 | 0.0 | 0.0 | 0.0 | 280.0 | 4.4K | 0.0 | 0.0 | 0.0 | 0.0 | 3.5K | -69K | 8.4K | |
(12.5M) | (37.4M) | (1.6M) | -19.3M | -50.2M | -1.2M | -847K | (0.0) | -268.7K | (0.0) | (0.0) | -22.3K | -62.4K | -70.5K | -78.3K | -95.4K | -59.9K | -53.4K | -130.5K | -59.4K | |
FINANCING ACTIVITIES | ||||||||||||||||||||
14.1M | 0.0 | 0.0 | 0.0 | 0.0 | 69.1M | 81.7M | 0.0 | 16.8M | 0.0 | 0.0 | 3.6M | 0.0 | 8.8M | -96K | 14.1M | 1.4M | 0.0 | 2.7K | 9.9M | |
0.0 | 0.0 | 38.8M | 0.0 | -11K | -11K | -42K | 0.0 | -44.9K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 214.8K | 201.6K | -299.6K | -12.4K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -96K | -232.7K | (0.0) | (0.0) | (0.0) | (0.0) | |
795K | 3.5M | 1.6M | 900K | 64.1M | -5M | -4.6M | 0.0 | -1.1M | 0.0 | 0.0 | -335.6K | 0.0 | -568.3K | -2.2K | -430.5K | -35.8K | 129K | 0.0 | -710.1K | |
14.9M | 3.5M | 40.4M | 900K | 64.1M | 64M | 77.1M | 0.0 | 15.7M | 0.0 | 0.0 | 3.3M | 0.0 | 8.2M | -98.3K | 13.9M | 1.6M | -170.5K | -9.7K | 9.2M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | -16K | -26K | 41.3M | 133K | 3K | 0.0 | 75.1K | 0.0 | 0.0 | 94.1K | 23.9K | -6.9K | -1.8K | -355.2K | -84.5K | 30.3K | 0.0 | 0.0 | |
-3.8M | -8.1M | 4M | -37.5M | 37.1M | 37.1M | 53.5M | 0.0 | 5.9M | 0.0 | 0.0 | -397.7K | -6.2M | 2M | -4.6M | 10.1M | 278.4K | -3.2M | -3.5M | 2.7M | |
14.1M | 22.1M | 18.2M | 55.7M | 73.8M | 73.8M | 20.4M | 0.0 | 2.1M | 0.0 | 0.0 | 2.1M | 9.4M | 6.9M | 13.1M | 4.4M | 2.5M | 5.5M | 11.3M | 6.2M | |
10.2M | 14.1M | 22.1M | 18.2M | 110.9M | 110.9M | 73.8M | 0.0 | 8.1M | 0.0 | 0.0 | 1.7M | 3.2M | 9M | 8.5M | 14.5M | 2.8M | 2.2M | 7.8M | 8.8M | |
-32.2M | -58.3M | -39.5M | -19.6M | -18.5M | -27.1M | -23.6M | 0.0 | -9.8M | 0.0 | 0.0 | -3.8M | -6.2M | -6.2M | -4.5M | -3.4M | -1.2M | -3.1M | -3.6M | -6.5M |
SEC Filings
RCEL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
S-3 S-3 N/A | March 31, 2026 | March 31, 2026 | ||
10-K 10-K 2025 FY FY | February 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 01, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your RCEL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.